Johnson & Johnson (NYSE:JNJ) shares acquired by Allo Mutual Pension Insurance Company


Elo Mutual Pension Insurance Co boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating ) by 2.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). After adding another 5 thousand 742 shares during this period, the fund has 2 lakh 3 thousand 647 shares. Johnson & Johnson makes up approximately 1.0% of Elo Mutual Pension Insurance Company’s portfolio, making the stock its 14th largest holding. Elo Mutual Pension Insurance Company’s holdings in Johnson & Johnson were worth $36,092,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sloy Dahl & Holst LLC boosted its holdings in Johnson & Johnson by 7.5% in the first quarter. Sloy Dahl & Holst LLC now owns 6,245 shares of the company’s stock worth $1,107,000 after buying an additional 436 shares during the period. WMS Partners LLC boosted its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. WMS Partners LLC now owns 75,996 shares of the company’s stock valued at $13,469,000 after acquiring an additional 2,586 shares in the last quarter. State Treasurer North Carolina grew its stake in shares of Johnson & Johnson by 1.2% in the first quarter. The state treasurer of North Carolina now owns 1,171,014 shares of the company’s stock valued at $207,539,000 after acquiring an additional 14,123 shares during the period. Advisors Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 6.1% in the first quarter. Advisors Capital Management LLC now owns 284,971 shares of the company’s stock valued at $50,505,000 after purchasing an additional 16,467 shares during the last quarter. Finally, Silver Oak Securities Inc. acquired a new position in Johnson & Johnson in the first quarter valued at $1,200,000. Institutional investors and hedge funds own 68.78% of the company’s stock.

Johnson & Johnson’s turnover rose 1.5%

Shares of Johnson & Johnson stock opened at $169.31 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The firm has a market capitalization of $445.15 billion, a PE ratio of 24.64, a P/E/G ratio of 3.17 and a beta of 0.59. The firm’s 50-day moving average price is $173.43 and its 200-day moving average price is $174.56.

Johnson & Johnson (NYSE:JNJ – Get Rating ) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the prior year, the business posted earnings of $2.48 per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.67%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Internal Transactions at Johnson & Johnson

In related news, EVP Catherine E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In other news, EVP Catherine E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00 for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which is available through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00 for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. Disclosures for this sale can be found here. 0.35% of company shares are owned by insiders.

Analysts set new price targets

A number of research firms have weighed in on JNJ. Morgan Stanley lifted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. UBS Group decreased their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. SVB Leerink reduced their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Finally, Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89, according to MarketBeat.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, along with its subsidiaries, researches and develops, manufactures, and sells a variety of products in the global healthcare sector. The Company’s Consumer Health segment offers infant care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; AVEENO, CLEAN & CLEAR, SKIN HEALTH/BEAUTY PRODUCTS UNDER DR.

Further reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Get Rating ) .

Institutional Ownership for Johnson & Johnson (NYSE:JNJ) by Quarter



Get news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.